Wellington House, East Road, Cambridge CB1 1BH UK www.funxionaltherapeutics.com

Funxional Therapeutics

Funxional Therapeutics (FXT) develops new anti-inflammatory drugs. Inflammation is an important process in a wide range of common diseases, including autoimmune disorders (rheumatoid arthritis, multiple sclerosis and lupus, for example), asthma, heart disease and even neurodegeneration. Unfortunately, inflammation is also essential for preventing infections, and it is tricky to reduce the inflammation associated with disease without side-effects. As a result, many of today's best anti-inflammatory drugs, such as corticosteroids cause undesirable side-effects which limit the dose and duration of treatment.

FXT has developed a series of chemokine inhibitors that block the communication between white blood cells, and gently reduce inflammation. Early studies suggests this achieves a better balance between anti-inflammatory efficacy and safety than many existing pharmaceuticals.

FXT was formed in August 2005, as a spin-out from the French pharmaceutical group Ipsen and Cambridge University, with a management team assembled by Total Medical Ventures. FXT is also supported by Index Ventures and Novo Ventures. Its lead product, the chemokine inhibitor, FX125L, successfully completed Phase I clinical trials in the USA in 2009.